Home / Hair Loss

Crown vs Frontal Hair Loss: Why Pattern Matters

Written by James T.

Published February 24, 2026

Where your hair thins first is not random — it predicts how your hair loss will progress and which treatments are most likely to slow it.

Understanding Hair Loss Pattern in Men

Androgenetic alopecia (AGA) — the medical term for male-pattern hair loss driven by hormones and genetics — does not affect every part of the scalp equally. The two most clinically distinct presentations are crown thinning (vertex loss) and frontal thinning (hairline recession), and distinguishing between them matters before any treatment decision is made.

The difference is not cosmetic preference. It is pharmacology.

How Androgenetic Alopecia Works

The primary driver of AGA is dihydrotestosterone (DHT), a potent androgen (male sex hormone) converted from testosterone by an enzyme called 5-alpha reductase. Hair follicles in genetically susceptible scalp regions contain androgen receptors that, when repeatedly exposed to DHT, undergo miniaturization — a gradual shrinking of the follicle that produces thinner, shorter, lighter hairs until the follicle becomes dormant.

Critically, follicle sensitivity to DHT is not uniform across the scalp. The vertex (crown) and the frontotemporal hairline carry the highest receptor density in most men. The occipital region (back and sides) is largely DHT-resistant — which is why hair there persists even in advanced loss, and why donor hair from that zone is used in transplant surgery.

The Norwood Scale: A Common Clinical Framework

The Norwood-Hamilton scale is the most widely used classification system for male-pattern hair loss. It runs from Type I (minimal recession, essentially a full hairline) through Type VII (only a horseshoe band of hair remaining at the sides and back).

Clinically, the scale breaks into two major tracks:

• Types II–IV: Predominantly frontal and temporal recession — the hairline moves backward, and a defined widow's peak or "M-shape" emerges.
• Types IV–VI (vertex variant): Prominent crown thinning that may exist alongside or independent of frontal recession, eventually merging with the frontal zone in higher types.
• Type VII: Confluent loss across the entire top of the scalp.

Why does this matter? Because the two primary evidence-based medical therapies — oral finasteride and topical minoxidil — do not perform identically at all scalp zones.

Evidence Base: What the Trials Show

Finasteride is an oral 5-alpha reductase inhibitor that reduces circulating DHT by approximately 70%, according to the prescribing pharmacology literature. A pivotal trial published in the *Journal of the American Academy of Dermatology* followed 1,553 men with mild-to-moderate vertex hair loss over two years and demonstrated statistically significant increases in hair count and hair weight at the vertex compared to placebo. Frontal scalp response was measurable but consistently more modest across the trial data — a pattern replicated in subsequent studies. Results may vary.

Minoxidil is a vasodilator (a drug that widens blood vessels) originally developed for hypertension. Its mechanism in hair loss is not fully characterized, but it is believed to prolong the anagen (active growth) phase of the hair cycle and increase follicular blood flow. Topical formulations have demonstrated efficacy at both the vertex and the frontal scalp, with peer-reviewed research suggesting vertex response tends to be more robust, though frontal application is supported by clinical evidence as well. Results may vary.

A 2022 review in the *Journal of the American Academy of Dermatology* examined combination therapy — finasteride plus minoxidil — and found additive benefit over either agent alone, particularly at the vertex, but with meaningful frontal retention as well. The authors noted that early intervention, before follicles reach terminal miniaturization, is the strongest predictor of treatment response regardless of pattern.

Who Is and Is Not a Candidate

Potentially appropriate candidates for medical hair-loss therapy include men who:

• Have confirmed AGA (pattern loss, not diffuse or patchy loss, which may indicate other diagnoses)
• Are experiencing active thinning, not already fully bald in the affected region
• Have no contraindications to the specific agent

Finasteride is contraindicated in:

• Men with a history of hypersensitivity to the drug
• Men with hepatic (liver) impairment, as the drug is metabolized hepatically
• Men planning conception in the near term — finasteride affects seminal DHT, and the prescribing provider should discuss reproductive considerations

Clinically important note on finasteride and cardiovascular health: During American Heart Month, it is worth flagging that erectile dysfunction (ED) — a known, albeit uncommon, potential side effect of finasteride — is also one of the earliest clinical warning signs of underlying cardiovascular disease. Endothelial dysfunction, the impaired ability of blood vessels to dilate, is shared pathophysiology between ED and atherotherosis (arterial plaque disease). If you are experiencing ED unrelated to any medication, the American Heart Association recommends discussing cardiovascular risk with your provider. Do not dismiss it as an isolated issue.

Minoxidil topical is generally well-tolerated but should be used with caution in men with known cardiac arrhythmias or hypotension (low blood pressure). Scalp irritation and initial shedding (telogen effluvium, a temporary increase in hair shedding as new growth cycles begin) are the most common early complaints.

What to Expect on Treatment

• Timeline: Neither therapy produces visible results overnight. Finasteride's DHT suppression begins within days, but observable hair retention typically requires three to six months. Minoxidil's cosmetic effect is usually apparent by four to six months. Full assessment of response is generally deferred to twelve months.
• Initial shedding: Topical minoxidil commonly triggers a transient shedding phase in the first four to eight weeks. This is not failure — it reflects the follicle cycling into a new anagen phase. It typically resolves on its own.
• Continued use required: Both agents require ongoing use to maintain effect. Discontinuation is followed by resumed loss, usually returning to the pre-treatment trajectory within twelve months.
• When to contact your provider: Report any sexual side effects (decreased libido, ejaculatory changes), nipple tenderness, or skin reactions promptly through your patient portal. Do not raise medical concerns with support staff — direct them to your licensed provider.

The Good Guy Rx Pathway

Good Guy Rx is a technology platform that connects men to independent licensed physicians and independent state-licensed pharmacies. If you are noticing a change in your hairline or crown, the prescribing provider determines whether finasteride or topical minoxidil is appropriate after a thorough medical intake — including a review of your hair loss pattern, your health history, and any medications you are currently taking. Compounded formulations, when prescribed, are prepared by state-licensed compounding pharmacies in accordance with FDA regulations and are not FDA-approved products. Start your online hair-loss assessment to connect with a provider.

Sources

• Finasteride Vertex Hair Loss Trial — Journal of the American Academy of Dermatology — https://pubmed.ncbi.nlm.nih.gov/9362463/
• Combination Finasteride + Minoxidil Review — Journal of the American Academy of Dermatology — https://pubmed.ncbi.nlm.nih.gov/35190188/
• Norwood-Hamilton Scale Overview — American Hair Loss Association — https://www.americanhairloss.org/men_hair_loss/the_norwood_scale.html
• Androgenetic Alopecia — StatPearls, NIH/NCBI — https://www.ncbi.nlm.nih.gov/books/NBK430924/
• Erectile Dysfunction as a Cardiovascular Risk Marker — American Heart Association — https://www.heart.org/en/health-topics/sexual-health/erectile-dysfunction-and-heart-disease
• Minoxidil Mechanism and Efficacy — Dermatology and Therapy, NIH/NCBI — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649274/

This article is educational. A licensed provider determines whether you are a candidate after a medical intake.

Ready to start your journey?

Complete your free online visit and see if GLP-1 treatment is right for you.

Get Started

Related Articles

Oral Minoxidil vs Topical: What the Evidence Says

James T. · Jul 1, 2026

Hair Loss Confidence Men Over 40: The Lie I Told Myself

Todd Chrisley · May 10, 2026